Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo's proposal to unveil a three- year plan for exploiting synergies in operations to enhance their generic and branded business worldwide has been delayed by two months.
Ranbaxy Chief Executive Officer and Managing Director Atul Sobti today said that the three-year plan, which was to be announced in January 2010 will be announced in March.
He, however, declined to give specific date for the announcement of synergy plan.
The plan is aimed at enhancing value of both the companies with a focus on branded drugs, its back-end support, which includes research and development, and marketing.
"We are looking at better co-operation with Daiichi Sankyo as we are focussing on biologicals and vaccines also," Sobti said while adding that the company is also looking at exporting drugs to Japan from its facilities in India.
Market analysts had predicted that the synergy plan between the two companies could address issues such as accessing the Japanese market and leveraging on Ranbaxy's distribution network to launch its products in other markets.
The company added that its Batamandi facility at Paonta Sahib has got approval of Japanese healh regulator, PMDA.
Last year, both companies have entered into an pact under which Ranbaxy would market the branded products from Daiichi Sankyo's portfolio in the markets where the Japanese firm did not have presence.
The Gurgaon-based company had launched Evista, a drug used for treating osteoporosis, through its subsidiary in Romania from Daiichi Sankyo's portfolio. In Mexico, Ranbaxy has set-up a new marketing division to focus on Daiichi Sankyo's product.
Besides this, Ranbaxy has also introduced some of Daiichi Sankyo's product in India.
Daiichi Sankyo acquired majority stake in Ranbaxy Laboratories in 2008 for about Rs 22,000 crore.
